Loading...
TYRA logo

Tyra Biosciences, Inc.NasdaqGS:TYRA Stock Report

Market Cap US$1.9b
Share Price
US$32.47
US$51.15
36.5% undervalued intrinsic discount
1Y268.1%
7D-3.9%
1D
Portfolio Value
​
View

Tyra Biosciences, Inc.

NasdaqGS:TYRA Stock Report

Market Cap: US$1.9b

Tyra Biosciences (TYRA) Stock Overview

A clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. More details

TYRA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 78.51% per year

Analysts in good agreement that stock price will rise by 57.5%

Risk Analysis

Earnings are forecast to decline by an average of 1.5% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


TYRA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Tyra Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Tyra Biosciences
Historical stock prices
Current Share PriceUS$32.47
52 Week HighUS$40.65
52 Week LowUS$8.75
Beta0.79
1 Month Change-13.62%
3 Month Change-5.88%
1 Year Change268.14%
3 Year Change131.60%
5 Year Changen/a
Change since IPO24.88%

Recent News & Updates

Recent updates

Analysis Article • Oct 01

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 28

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Mar 01

Tyra Biosciences: FGFR1/2 Driven AE Data Spooked The Market

Summary Tyra Biosciences' TYRA-300, an oral FGFR3 inhibitor, showed promising efficacy but raised concerns with some FGFR1/2-driven adverse events, causing a significant stock drop. TYRA-300 demonstrated better safety and tolerability compared to erdafitinib, with fewer high-grade toxicities and lower incidence of hyperphosphatemia and other side effects. Financially, Tyra has a market cap of $632mn, a cash balance of $360mn, and a cash runway of 11–20 quarters, depending on expenses. The market's reaction to TYRA-300's data was mixed; further data from the SURF301 trial is needed to make a definitive investment decision. Read the full article on Seeking Alpha
Seeking Alpha • Dec 17

The Take On Tyra Biosciences

Summary Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse event profile and tepid duration of response at 90mg. TYRA-300 aims to overcome limitations of existing mUC therapies like Balversa, with ongoing trials at higher 120mg doses and other cancer/genetic indications. Despite safety concerns, analysts remain bullish on Tyra, with unanimous Buy ratings and price targets between $28 and $33 per share. RA Capital Management increased its stake in Tyra, signaling confidence, but the path to first-line therapy approval remains uncertain pending further data. An analysis around Tyra Biosciences follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Dec 11

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 21

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights Tyra Biosciences' estimated fair value is US$25.61 based on 2 Stage Free Cash Flow to Equity Tyra...
Seeking Alpha • Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Summary Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 towards a phase 2 study for metastatic urothelial carcinoma and non-muscle invasive bladder cancer patients. TYRA-300 also shows potential for treating skeletal dysplasia disorders, with an IND filing for achondroplasia expected in the second half of 2024. TYRA has a strong cash position, with $373.8 million as of June 30, 2024, sufficient to fund operations into 2026. Read the full article on Seeking Alpha
Analysis Article • Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 23

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Summary Tyra Biosciences, Inc. has no revenue or earnings, but share prices have increased by 32.68% in the past year. The company focuses on precision medicines targeting FGFR biology, with future promise in oncology and genetic conditions. Despite bullish signals, the lack of key fundamentals makes Tyra a speculative play, rated as a Hold with potential for growth. Read the full article on Seeking Alpha
Analysis Article • Jul 05

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Key Insights The projected fair value for Tyra Biosciences is US$18.25 based on 2 Stage Free Cash Flow to Equity Tyra...
Analysis Article • May 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 13

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 27

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 13

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tyra Biosciences...
Analysis Article • Feb 23

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Nov 09

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 04

Tyra Biosciences GAAP EPS of -$0.36

Tyra Biosciences press release (NASDAQ:TYRA): Q2 GAAP EPS of -$0.36. As of June 30, 2022, TYRA had cash and cash equivalents of $275.1 million.
Analysis Article • Jul 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

TYRAUS BiotechsUS Market
7D-3.9%3.1%1.2%
1Y268.1%34.6%28.7%

Return vs Industry: TYRA exceeded the US Biotechs industry which returned 34.6% over the past year.

Return vs Market: TYRA exceeded the US Market which returned 28.7% over the past year.

Price Volatility

Is TYRA's price volatile compared to industry and market?
TYRA volatility
TYRA Average Weekly Movement7.1%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Stable Share Price: TYRA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: TYRA's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201887Todd Harristyra.bio

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.

Tyra Biosciences, Inc. Fundamentals Summary

How do Tyra Biosciences's earnings and revenue compare to its market cap?
TYRA fundamental statistics
Market capUS$1.93b
Earnings (TTM)-US$131.10m
Revenue (TTM)n/a
0.0x
P/S Ratio
-14.7x
P/E Ratio

Is TYRA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TYRA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$131.11m
Earnings-US$131.10m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-2.20
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TYRA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/26 16:53
End of Day Share Price 2026/05/22 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tyra Biosciences, Inc. is covered by 19 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Eliana MerleBarclays
Jason ZemanskyBofA Global Research
John NewmanCanaccord Genuity